UK at risk of losing lead in stem cell research
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Britain's attempts to take stem cell research from the laboratory to the clinic are being undermined by government red tape and a lack of interest from City investors, according to experts meeting in London today.
Scientists behind Britain's dominant position in stem cell research said they are hampered by the number of regulatory authorities that have to be consulted and a lack of funding from the UK. Funds are more likely to come from the Middle East and America, with the risk that British innovations will go abroad, according to members of the UK National Stem Cell Network, which represents leaders in the field.
The risk of stem-cell breakthroughs being taken to the US will become more likely under Barack Obama, who has promised to prioritise stem cell science.
Professor Pete Coffey, a stem cell scientist at the Institute of Ophthalmology at University College London, said his pioneering research into treating blindness was being funded by two US foundations. He is resisting pressure to take the project to California. "I can do it in the UK – slowly. If I took it to the US, I could accelerate it. I know of 16 projects in a similar position."
Professor John Sinden, chief executive of the research company ReNeuron, said his work in treating strokes with stem cells is being funded from Saudi Arabia due to a lack of interest here. There are four government bodies involved in regulating stem cell research, making it hard to negotiate the red tape required to reach clinical trials.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments